IQVIA Inc.
IQVIA Inc. stands as a global market leader in life sciences research and commercial outsourcing, with a dominant position in the AI in Clinical Trials market, primarily through its expansive eClinical solutions portfolio. The company’s strategy centers on leveraging its global presence and technological scale to deliver integrated clinical and commercial solutions. IQVIA utilizes AI and data analytics to decentralize trial operations, which helps to shorten clinical trial timelines, enhance patient experience, and improve overall data quality. This is achieved through solutions that span the entire R&D and commercialization spectrum, from early-stage development to post-market surveillance. A key focus area for IQVIA is expanding its services in high-growth regions like China, India, and Japan, often strengthened by strategic acquisitions such as Q2 Solutions, which broadens their service offerings in the Research & Development Solutions business division. Their continued R&D investment and focus on integrated solutions secure their critical role in advancing AI adoption for efficient and high-quality clinical research worldwide.
Latest Market Research Report on AI in Clinical Trials Download PDF Brochure Now
Dassault Systèmes (Medidata)
Dassault Systèmes, through its Medidata platform, is a significant provider in the AI in Clinical Trials market, offering end-to-end, global clinical data gathering and management capabilities. Medidata’s solutions leverage AI to manage and analyze vast amounts of clinical data, providing a comprehensive set of features for a wide range of study requirements, thereby ensuring a strong market position and high industry expertise. The company focuses heavily on organic growth through continuous innovation and platform upgrades. A prime example is the introduction of the native mobile application, MyMedidata, which utilizes a single sign-on to simplify patient experiences by allowing direct mobile access to critical trial functionalities like electronic diaries, patient-reported outcomes, and informed consent. By making participation simpler and more accessible, Medidata’s AI-enhanced platform helps to improve patient engagement and data collection quality. The company also employs inorganic means, such as strategic partnerships and acquisitions, to further solidify its market standing and expand its integrated clinical solutions.
Saama
Saama is recognized as a leading provider of AI and advanced analytics solutions tailored specifically for the life sciences industry, playing a transformative role in optimizing clinical trial operations. The company’s platform is designed to leverage sophisticated machine learning algorithms for real-time analysis of clinical data, which is applied across the entire trial lifecycle, from patient recruitment to data management and regulatory compliance. Saama’s AI-driven analytics are instrumental in streamlining patient recruitment by efficiently identifying eligible participants, significantly reducing the time and resources traditionally required for this bottleneck phase. Furthermore, their solutions are crucial for enhancing data integrity, ensuring regulatory adherence, and providing deeper, actionable insights into complex clinical data. This enables researchers to make faster, more informed decisions and accelerate the development of innovative treatments. Saama’s commitment to innovation in this space was recently recognized when it was awarded “Best AI-Based Solution for Life Sciences” at the AI Breakthrough Awards 2024, validating its position as a key driver of data-driven transformation in clinical trials.
Tempus AI, Inc.
Tempus AI, Inc. is an AI-enabled precision medicine company that has established a powerful presence in clinical trials by leveraging one of the world’s largest collections of de-identified clinical and molecular data. The company’s core offering is its vast data ecosystem, which is connected to approximately 65% of all Academic Medical Centers in the US and partners with over 95% of the top 20 pharma oncology companies. Tempus uses its generative AI platform to power scientific discovery and improve patient outcomes across various segments, including oncology. Its platform includes AI-enabled tools like ONE for healthcare providers, NEXT for identifying gaps in care, and LENS for accessing multimodal real-world data. Crucially for clinical trials, Tempus specializes in molecular profiling and clinical trial matching, having successfully identified over 40,000 patients for potential enrollment in its network. The company’s strategic moves, such as acquiring the digital pathology AI company Paige and integrating its generative AI clinical co-pilot, David, into Electronic Health Record (EHR) platforms, demonstrate its focus on integrating AI directly into the clinical workflow to speed up research and diagnostics.
Unlearn.ai, Inc.
Unlearn.ai, Inc. is a US-based AI company that is revolutionizing clinical trials by applying advanced generative AI and machine learning to address the significant challenge of control group sizes. Founded in 2017, the company’s innovative approach centers on creating “digital twin models,” which are predictive simulations of how a patient would progress if they were placed in a control group. By accurately simulating patient progression, this technology allows researchers to design trials with smaller physical control groups or use the generated data as a supplement to observed data. This use of AI significantly improves clinical trial efficiency, reduces the required sample size, and lowers operational costs. Unlearn.ai is particularly impactful in complex and slow-moving disease areas like Alzheimer’s research, where their technology has been demonstrated in collaborations with major pharmaceutical companies. By directly reducing the number of patients needed for a control arm, Unlearn.ai’s platform accelerates drug development, enhances trial design, and ultimately speeds up the delivery of new, effective treatments to the market.
Phesi
Phesi is a global leader in patient-centric data analytics that harnesses AI to fundamentally transform clinical trial design and patient recruitment strategies. Their core product is the Trial Accelerator Platform, an expansive AI-driven database that integrates data from over 100 million patients, including detailed Digital Patient Profiles (DPP) across 4,000 indications. This massive, patient-centric dataset empowers the company to offer highly accurate predictive trial modeling and simulations. By running these simulations, Phesi helps pharmaceutical companies optimize their protocols, predict patient enrollment feasibility, and make informed decisions about site selection long before a trial even begins. This predictive capability significantly reduces the guesswork and manual effort associated with traditional trial planning. By enhancing trial planning and reducing patient recruitment timelines, Phesi accelerates the adoption of AI for predictive modeling and validates its position as a key partner in driving the efficiency and quality of global clinical development.
Deep6.ai
Deep 6 AI offers an innovative platform that utilizes artificial intelligence, specifically Natural Language Processing (NLP), to solve the long-standing industry bottleneck of patient recruitment for clinical trials. The company’s technology is designed to analyze vast amounts of unstructured medical data, including complex electronic health records (EHRs), pathology reports, and free-text clinical notes, which are typically inaccessible to standard search methods. This deep analysis allows the platform to precisely identify potential trial candidates who meet the complex and specific inclusion and exclusion criteria of a given study, moving beyond unreliable billing codes. Critically, Deep 6 AI automates this labor-intensive patient screening process, drastically reducing the time required from weeks to minutes. This efficiency not only accelerates trial initiation and shortens overall trial durations but also helps to enhance participant diversity, ultimately accelerating the advancement and delivery of life-saving medical research.
AIwithCare
AIwithCare is an emerging company spun out of Mass General Brigham’s Accelerator for Clinical Transformation, focusing on deploying generative AI to accelerate patient screening and recruitment for clinical trials. The company’s flagship platform, AIwithCare Studio, incorporates the powerful RECTIFIER (RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review) tool. RECTIFIER is built on large language models (LLMs) to accurately interpret the full clinical context of both structured and unstructured patient data found within electronic health records. This sophisticated interpretation overcomes the inaccuracies of relying solely on messy medical records or billing codes for eligibility. In studies, the use of RECTIFIER has demonstrated significant improvements in patient enrollment rates, with one randomized trial finding enrollment to be almost double that of traditional manual screening, at a lower cost. AIwithCare’s mission is to scale this capability to hospitals and healthcare systems globally, enabling them to automatically evaluate large patient populations against complex trial criteria and drive a major efficiency gain in clinical research operations.
PhaseV
PhaseV is a leader in applying AI and Machine Learning (AI/ML) to optimize end-to-end clinical development, quickly establishing itself as a key industry partner. Their AI-driven platform offers full platform subscriptions across four integrated modules, focusing on trial design and execution. PhaseV’s technology provides measurable Return on Investment (ROI) for sponsors by optimizing protocols through running millions of virtual design simulations in minutes. This advanced modeling capability helps to identify the optimal trial design, leading to trials that run up to 40% faster and at 50% lower cost than traditional methods. Furthermore, the platform is essential for optimizing site selection and enabling real-time trial monitoring and execution, helping sponsors improve their probability of success (PoS) by more than 30%. PhaseV’s success is validated by its rapid growth, significant funding, and partnerships with over 40 leading pharma sponsors and CROs, including seven of the world’s top pharmaceutical companies, positioning it as a transformative force in the clinical trial optimization landscape.
Antidote Technologies, Inc.
Antidote Technologies, Inc. is a specialist in the AI in Clinical Trials market, focusing primarily on the critical function of patient-trial matching. Established in 2013 and based in the US, the company leverages AI and machine learning algorithms to bridge the gap between patients and relevant clinical research studies. Antidote’s core technology intelligently analyzes a patient’s medical profile against the complex and often restrictive inclusion and exclusion criteria of clinical trials. By automating and streamlining this process, the company dramatically enhances recruitment efficiency, helping to reduce the time-consuming and expensive recruitment phase, which is a major factor in overall trial length. As the global demand for faster and more efficient trials grows, Antidote’s solutions play a vital role in accelerating trial timelines and ensuring that researchers can quickly and accurately connect with the most suitable participants, thereby driving progress in biopharmaceutical development and reducing overall trial costs.
Latest Market Research Report on AI in Clinical Trials Download PDF Brochure Now